The nanomedicine-based chemoimmunotherapy substantially ameliorated the anti-tumor effect comparing to PG@KMCM nanomedicine (PG@KMCM + α-PD-L1 9.2 ± 2.6 mg vs. PG@KMCM 17.4 ± 1.1 mg; ± s.d., n = 5; p < 0.001, one-way ANOVA followed by Student’s t-test) or α-PD-L1 immunotherapy alone (vs. α-PD-L1 22.2 ± 1.5 mg; ± s.d., n = 5; p < 0.001, Student’s t-test), suggesting synergism of inhibiting tumor growth between PG@KMCM and α-PD-L1 (Fig. 5b, c). Here, CD274 is linked to neoplasm.